Treatment Details – 15.0 months
|Patients: This Phase II study involved 31 patients with malignant pleural mesothelioma.|
Treatment: The treatment consisted of the injection of human recombinant Interleukin-2 (Proleukin).
Toxicity: Grade 3 toxicities included cardiac failure and fever. Grade 2 toxicities included neuropathy, neurologic, and gastrointestinal.
Results: Median overall survival was 15 months.
Correspondence: Bruno Castagneto, MD